Davide Prezzi1,2, Gauraang Bhatnagar1, Roser Vega3, Jesica Makanyanga1, Steve Halligan1, Stuart Andrew Taylor4. 1. Centre for Medical Imaging, University College London, 3rd floor east, 250 Euston Rd, London, NW1 2PG, UK. 2. Department of Cancer Imaging, King's College London, St Thomas' Hospital, 4th floor Lambeth Wing, London, SE1 7EH, UK. 3. Gastrointestinal Services, University College Hospital, Ground floor west, 250 Euston Road, London, NW1 2PG, UK. 4. Centre for Medical Imaging, University College London, 3rd floor east, 250 Euston Rd, London, NW1 2PG, UK. stuart.taylor1@nhs.net.
Abstract
OBJECTIVES: To assess the ability of magnetic resonance enterography global score (MEGS) to characterise Crohn's disease (CD) response to anti-TNF-α therapy. METHODS: Thirty-six CD patients (median age 26 years, 20 males) commencing anti-TNF-α therapy with concomitant baseline MRI enterography (MRE) were identified retrospectively. Patients' clinical course was followed and correlated with subsequent MREs. Scan order was randomised and MEGS (a global activity score) was applied by two blinded radiologists. A physician's global assessment of the disease activity (remission, mild, moderate or severe) at the time of MRE was assigned. The cohort was divided into clinical responders and non-responders and MEGS compared according to activity status and treatment response. Interobserver agreement was assessed. RESULTS: Median MEGS decreased significantly between baseline and first follow-up in responders (28 versus 6, P < 0.001) but was unchanged in non-responders (26 versus 18, P = 0.28). The median MEGS was significantly lower in clinical remission (9) than in moderate (14) or severe (29) activity (P < 0.001). MEGS correlated significantly with clinical activity (r = 0.53; P < 0.001). Interobserver Bland-Altman limits of agreement (BA LoA) were -19.7 to 18.5. CONCLUSIONS: MEGS decreases significantly in clinical responders to anti-TNF-α therapy but not in non-responders, demonstrates good interobserver agreement and moderate correlation with clinical disease activity. KEY POINTS: • MRI scores of Crohn's activity are used increasingly in clinical practice and therapeutic trials. • Such scores have been advocated as biomarkers of therapeutic response. • MEGS reflects clinical response to anti-TNF-α therapy and the clinical classification of disease activity. • MEGS demonstrates good interobserver agreement.
OBJECTIVES: To assess the ability of magnetic resonance enterography global score (MEGS) to characterise Crohn's disease (CD) response to anti-TNF-α therapy. METHODS: Thirty-six CDpatients (median age 26 years, 20 males) commencing anti-TNF-α therapy with concomitant baseline MRI enterography (MRE) were identified retrospectively. Patients' clinical course was followed and correlated with subsequent MREs. Scan order was randomised and MEGS (a global activity score) was applied by two blinded radiologists. A physician's global assessment of the disease activity (remission, mild, moderate or severe) at the time of MRE was assigned. The cohort was divided into clinical responders and non-responders and MEGS compared according to activity status and treatment response. Interobserver agreement was assessed. RESULTS: Median MEGS decreased significantly between baseline and first follow-up in responders (28 versus 6, P < 0.001) but was unchanged in non-responders (26 versus 18, P = 0.28). The median MEGS was significantly lower in clinical remission (9) than in moderate (14) or severe (29) activity (P < 0.001). MEGS correlated significantly with clinical activity (r = 0.53; P < 0.001). Interobserver Bland-Altman limits of agreement (BA LoA) were -19.7 to 18.5. CONCLUSIONS: MEGS decreases significantly in clinical responders to anti-TNF-α therapy but not in non-responders, demonstrates good interobserver agreement and moderate correlation with clinical disease activity. KEY POINTS: • MRI scores of Crohn's activity are used increasingly in clinical practice and therapeutic trials. • Such scores have been advocated as biomarkers of therapeutic response. • MEGS reflects clinical response to anti-TNF-α therapy and the clinical classification of disease activity. • MEGS demonstrates good interobserver agreement.
Authors: Jesica C Makanyanga; Doug Pendsé; Nikolaos Dikaios; Stuart Bloom; Sara McCartney; Emma Helbren; Elaine Atkins; Terry Cuthbertson; Shonit Punwani; Alastair Forbes; Steve Halligan; Stuart A Taylor Journal: Eur Radiol Date: 2013-09-12 Impact factor: 5.315
Authors: Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes Journal: Lancet Date: 2008-02-23 Impact factor: 79.321
Authors: J Panes; Y Bouhnik; W Reinisch; J Stoker; S A Taylor; D C Baumgart; S Danese; S Halligan; B Marincek; C Matos; L Peyrin-Biroulet; J Rimola; G Rogler; G van Assche; S Ardizzone; A Ba-Ssalamah; M A Bali; D Bellini; L Biancone; F Castiglione; R Ehehalt; R Grassi; T Kucharzik; F Maccioni; G Maconi; F Magro; J Martín-Comín; G Morana; D Pendsé; S Sebastian; A Signore; D Tolan; J A Tielbeek; D Weishaupt; B Wiarda; A Laghi Journal: J Crohns Colitis Date: 2013-04-11 Impact factor: 9.071
Authors: Michael J Steward; Shonit Punwani; Ian Proctor; Yvette Adjei-Gyamfi; Fiona Chatterjee; Stuart Bloom; Marco Novelli; Steve Halligan; Manuel Rodriguez-Justo; Stuart A Taylor Journal: Eur J Radiol Date: 2011-09-15 Impact factor: 3.528
Authors: Jeroen A W Tielbeek; Mark Löwenberg; Shandra Bipat; Karin Horsthuis; Cyriel Y Ponsioen; Geert R D'Haens; Jaap Stoker Journal: Inflamm Bowel Dis Date: 2013-08 Impact factor: 5.325
Authors: Jeroen A W Tielbeek; Jesica C Makanyanga; Shandra Bipat; Doug A Pendsé; C Yung Nio; Frans M Vos; Stuart A Taylor; Jaap Stoker Journal: AJR Am J Roentgenol Date: 2013-12 Impact factor: 3.959
Authors: C Hordonneau; A Buisson; J Scanzi; F Goutorbe; B Pereira; C Borderon; D Da Ines; P F Montoriol; J M Garcier; L Boyer; G Bommelaer; V Petitcolin Journal: Am J Gastroenterol Date: 2013-11-19 Impact factor: 10.864
Authors: Ryan W Stidham; Binu Enchakalody; Akbar K Waljee; Peter D R Higgins; Stewart C Wang; Grace L Su; Ashish P Wasnik; Mahmoud Al-Hawary Journal: Inflamm Bowel Dis Date: 2020-04-11 Impact factor: 5.325
Authors: Bruno Lima Rodrigues; Márcia Carolina Mazzaro; Cristiane Kibune Nagasako; Maria de Lourdes Setsuko Ayrizono; João José Fagundes; Raquel Franco Leal Journal: World J Gastrointest Endosc Date: 2020-12-16